Chemometric determination of rabeprazole sodium in presence of its acid induced degradation products using spectrophotometry, polarography and anodic voltammetry at a glassy carbon electrode.
Chemometric stability indicating methods are presented for the determination of rabeprazole sodium in presence of its acid induced degradation products using spectrophotometry, differential pulse polarography and differential pulse anodic voltammetry at a glassy carbon electrode. The applied chemometric techniques are multivariate ones including classical least squares (CLS), principal component regression (PCR) and partial least squares (PLS). A difference spectrophotometric (DeltaA) method has also been applied. To develop the multivariate calibrations, a training set was used, consisting of 20 mixture solutions of rabeprazole sodium and its degradation products. These mixtures show percentage degradation ranging from 0.5-65%, 0.5-95% and 0.6-75% for the spectrophotometric, polarographic and anodic voltammetric calibrations, respectively. The UV absorbances were recorded in 0.1 M NaOH within the wavelength range 220-340 nm at 2 nm intervals. The polarograms and anodic voltammograms were recorded in Britton-Robinson buffer (pH 8.0) within the potential range -500 to -1508 and 400 to 1192 mV at 6 mV intervals with a pulse amplitude of -100 and 50 mV, sweep rate of 15 and 10 mV s(-1) and pulse interval of 0.4 and 0.6 s for the polarographic and anodic voltammetric methods, respectively. All the studied methods have been validated and successfully applied to the determination of rabeprazole sodium in tablet dosage form. The results were statistically compared to those obtained using a published HPLC method. No significant difference has been found.
Moneeb
Marwa S
MS
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, University of Alexandria, Alexandria, Egypt. marwamoneeb@yahoo.com
D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000737:chemistry*; D002021:Buffers; D002138:Calibration; D002244:Carbon; D004355:Drug Stability; D004566:Electrodes / Q000592:standards; D004867:Equipment Design; D005079:Excipients / Q000737:chemistry; D006863:Hydrogen-Ion Concentration; D016018:Least-Squares Analysis; D008956:Models, Chemical; D015233:Models, Statistical; D011048:Polarography / Q000295:instrumentation* / Q000592:standards; D011199:Potentiometry / Q000295:instrumentation* / Q000592:standards; D025341:Principal Component Analysis; D054328:Proton Pump Inhibitors / Q000737:chemistry*; D064750:Rabeprazole; D015203:Reproducibility of Results; D012972:Sodium Hydroxide / Q000737:chemistry; D013056:Spectrophotometry, Ultraviolet / Q000592:standards; D013607:Tablets
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D002021:Buffers; D005079:Excipients; D054328:Proton Pump Inhibitors; D013607:Tablets; D064750:Rabeprazole; D012972:Sodium Hydroxide; D002244:Carbon